Michael Shuster provides strategic intellectual property legal services to biotechnology and chemical/pharmaceutical companies. His practice includes patent prosecution, portfolio analysis, due diligence, litigation and opinion work. His clients include start-up and established biotechnology companies, venture capital firms and research universities and hospitals. He marries a deep scientific and technical background, cutting-edge legal experience and pragmatic business acumen to help his clients advance and protect highly complex crossover technologies.
Michael has legal and technical experience in immunotherapy, antibody technologies, microbiome-based technologies, ag biotechnology, biologics, gene therapy, therapeutic vaccines, synthetic biology, small molecule therapeutics and drug formulations.
Michael’s IP due diligence evaluation and counseling are critical to his clients’ businesses in the context of raising and investing growth capital, executing strategic partnerships and M&A transactions and going public. Representative recent matters in which he served as IP lead:
- Seres Therapeutics partnership with Nestle Health Sciences valued up to $1.9 billion
- Crescendo Biosciences $270 million acquisition by Myriad Genetics
- ProNAi Therapeutics $158 million IPO
- Seres Therapeutics $140 million IPO
- Bold Threads Series A and B financings raising a combined $40 million
- Google Ventures investment in Forty Seven's $75 million Series A financing
In 2016, Michael joined the advisory board of CalBIO, the biotech division of the California Technology Counsel. Currently, Michael is a co-instructor of "A Life Scientist's Guide to Intellectual Property" at UCSF, and regularly lectures about intellectual property law subjects. He is past chair of the Intellectual Property section of the Barrister's Club of San Francisco.
Before becoming an attorney, Michael’s career experience included graduate research in the laboratory of Professor Eric Kandel at Columbia University as part of a team focused on discovery of mechanisms by which short-term memories are stored, research for which Professor Kandel was awarded the 2000 Nobel Prize in Medicine. Michael then moved to the Department of Biochemistry and Biophysics at the University of California, San Francisco, where he pursued his interests in ion channel biophysics and protein structure.
Michael was named one of Top 25 Biotech Lawyers in California in 2011 and one of the Top 25 Intellectual Property Portfolio Managers in 2009 and 2012 by the Daily Journal. He was also recognized for patent prosecution in The Legal 500’s 2014 guide, as a "Life Sciences Star" for his outstanding patent work in Euromoney's LMG Life Sciences 2012, 2013 and 2016, as a Northern California “Super Lawyer” in 2013 and 2014, as well as an IP Star by Managing Intellectual Property in 2014, 2015 and 2016.
Michael received his B.A. from Brandeis University, magna cum laude, and his Ph.D. from Columbia University. He received his J.D., cum laude, from the University of San Francisco School of Law. Michael is registered to practice before the USPTO and is a member of the State Bar of California and Commonwealth of Massachusetts.